ramucirumab
Overview
Ramucirumab is a human monoclonal antibody targeting VEGFR2 (KDR), blocking VEGF-mediated angiogenic signaling. It is approved as second-line therapy in hepatocellular carcinoma (HCC) for patients with serum AFP ≥400 ng/mL — the first biomarker-selected approval in HCC.
Evidence in the corpus
- REACH-2 trial (AFP ≥400 ng/mL HCC): ramucirumab median OS 8.5 vs 7.3 months (HR 0.71, 95% CI 0.53–0.95, P=0.0199); first positive biomarker-enriched phase III trial in HCC; approved second-line for AFP-high patients PMID:24798001.
- Ramucirumab + durvalumab combination under evaluation (NCT02572687) as part of anti-VEGF/VEGFR + anti-PD-(L)1 combination strategies PMID:24798001.
- TCGA gastric adenocarcinoma (n=295) identified recurrent focal amplification of VEGFA (7%) in the chromosomal instability (CIN) subtype, providing genomic rationale for VEGFR2-pathway inhibition with ramucirumab in CIN-enriched gastric cancer PMID:25079317.
- Ramucirumab + docetaxel was administered as a later-line regimen in the WCM117 rapid-autopsy case of the WashU urothelial carcinoma WES cohort (n=32 patients), following cisplatin + gemcitabine first-line; illustrates treatment sequencing in chemotherapy-refractory BLCA PMID:27749842
Resistance mechanisms
Cancer types (linked)
Sources
- PMID:27749842 — Faltas et al. 2016, Nature Genetics. WashU UC WES cohort; ramucirumab + docetaxel later-line context in chemotherapy-refractory urothelial carcinoma.
This page was processed by entity-page-writer on 2026-05-15.